Caris Life Sciences Inc. (CAI) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Caris Life Sciences Inc. (CAI) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How CAI Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $812.0M | 44% | 5.6% | -$68.1M | $66.9M | 22.3% |
| FY 2024 | $412.3M | 44% | -62.4% | -$281.9M | -$253.6M | -45% |
| FY 2023 | $306.1M | 44% | -104.4% | -$341.4M | -$289.9M | -7.4% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring CAI)
- ✓Live walkthrough of CAI's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
CAI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +97.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CAI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CAI. Explore sector supply chains on /butterfly.
CAI Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Caris Life Sciences Inc. (CAI)?
In FY 2025 (10-K), CAI converted $812.0M of revenue into a 44% gross margin, 5.6% operating margin, and $66.9M in free cash flow (8.2% FCF margin).